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Abstract 
The tumor microenvironment consists of stromal cells and leukocytes that contribute to 
cancer progression. Cross-talk between tumor cells and their microenvironment is facilitated 
by a variety of soluble factors, including growth factors, cytokines such as chemokines. Due 
to a wide expression of chemokine receptors on cells in the tumor microenvironment, 
including tumor cells, chemokines affect various processes such as leukocyte recruitment, 
angiogenesis, tumor cell survival, tumor cell adhesion, proliferation, vascular permeability, 
immune suppression, invasion and metastasis. Inflammatory chemokines are instrumental 
players in cancer-related inflammation and significantly contribute to numerous steps during 
metastasis. Recruitment of myeloid-derived cells to metastatic sites is mainly mediated by the 
inflammatory chemokines CCL2 and CCL5. Tumor cell homing and extravasation from the 
circulation in distant organs are also regulated by inflammatory chemokines. Recent 
experimental evidence demonstrated that besides leukocyte recruitment, tumor cell-derived 
CCL2 directly activated endothelial cells and together with monocytes facilitated tumor cell 
extravasation, in a CCL2- and CCL5-dependent manner. Furthermore, CX3CL1 expression in 
the bone facilitated metastasis of CX3CR1 expressing tumor cells to this site. Current findings 
in preclinical models strongly suggest that inflammatory chemokines play an important role 
during metastasis and targeting of the chemokine axis might have a therapeutic potential. 
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Introduction 
Epidemiological studies have demonstrated that chronic inflammation predisposes individuals 
to development of various types of cancer, defining inflammation as a hallmark of cancer (1). 
Enhanced presence of inflammatory cells and soluble inflammatory mediators, such as 
cytokines and chemokines in the primary tumor are mostly associated with poor prognosis 
due to metastasis (2-4). However, the immune system has a dual role in cancer progression 
that depends on the cellular context of infiltrating cells and the tumor type (5). Chemokines 
and chemokine receptors play a key role in cancer-associated inflammation, where the 
chemokine-chemokine receptor axis affects both the composition and the function of cells 
within the tumor microenvironment (4, 6, 7). While the contribution of persistent 
inflammation to carcinogenesis is already recognized as a hallmark of cancer (1, 8, 9), there is 
accumulating evidence that chemokines significantly contribute to cancer progression and 
metastasis through distinct mechanisms (4, 10). 
Chemokines are chemotactic cytokines with many functions that are best known for their 
ability to induce directed migration of cells. Chemokines are produced by a number of 
different cells in response to cytokines (e.g. TNF superfamily members) and growth factors 
(e.g. TGF, PDGF). Their functions encompass movement of cells during inflammation, 
specific recruitment of lymphocytes, dendritic cells, macrophages and stem cells during 
leukocyte homing, organogenesis as well as cell polarization. Directed migration of cells 
expressing specific chemokine receptors occurs along a chemokine gradient towards higher 
local concentrations of ligand. Based on the cellular context and the site of expression, 
chemokines can be divided into “inflammatory chemokines” (e.g. CCL2, CCL5) which 
facilitate recruitment of cells during inflammation and “homeostatic chemokines” (e.g. 
CXCL12, CCL19), which are constitutively expressed in specific tissues (e.g. lymphoid 
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organs) and predominantly regulate homeostatic trafficking of leukocytes (2, 11). However, 
some chemokines seem to have dual functions that participate both in immune defenses 
during inflammation and in trafficking of non-effector leukocytes (12). Development of 
primary tumors and metastasis is influenced by the complex network of chemokines that 
regulate leukocyte recruitment and their activation which directly affects tumor growth, 
invasion and tissue-specific metastasis (2, 13). The role of homeostatic chemokines such as 
CXCL12, CCL19, and CCL21 in tissue-specific metastasis of different cancer cells 
expressing the corresponding chemokine receptors CXCR4 or CCR7 is well described and 
has been reviewed recently (11).  
In this review, we focus on the role of inflammatory chemokines and their receptors and 
summarize the current understanding of their distinct modes of action on stromal and 
hematopoietic cells during metastasis. We also discuss the potential and the limitations of a 
possible targeting of chemokines and chemokine receptors in the context of anti-metastatic 
treatment. 
 
Chemokines drive metastasis – initial experimental evidence 
The first report of a chemokine-dependent tissue-specific seeding of cancer cells has been 
described for breast cancer cells expressing CXCR4 that metastasized to the lung and lymph 
nodes due to local expression of the homeostatic chemokine CXCL12 (14). Later, the same 
chemokine axis was identified in melanoma cells (15). CXCL12 is the sole ligand for CXCR4 
that is also expressed in the bone marrow (BM) and liver (16, 17). Accordingly, breast cancer 
cells metastasize to these organs in a CXCR4-dependent manner.  
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Another chemokine receptor CCR7 has been implicated in melanoma metastasis to lymph 
nodes (18). Its two ligands, homeostatic chemokines CCL19 and CCL21, are preferentially 
expressed in secondary lymphoid tissues, and CCL19 is also expressed in the brain (19). 
CCL19 expression by endothelial cells in the brain is essential for CCR7-expressing T-ALL 
leukemic cells to specifically seed and to metastasize to this tissue (20). Since the initial 
reports on homeostatic chemokines as facilitators of tissue-specific metastasis, several other 
tumor cells from prostate, lung, colorectal, gastric and brain cancer were shown to express 
corresponding chemokine receptors that facilitate metastasis (11). In contrast, the expression 
of inflammatory chemokines is induced by an inflammatory trigger that could be derived 
either from tumor cells or stromal cells (21). Recent clinical evidence together with 
preclinical data identified several inflammatory chemokines (CCL2, CCL5, CXCL8, 
CX3CL1) as promoters of cancer progression and metastasis.   
 
Inflammatory chemokines and cancer - clinical evidence  
CCL2 and CCL5 are connected with cancer progression and particularly with metastatic 
disease. High levels of CCL2 and/or CCL5 have been associated with a poor outcome and 
shorter disease-free survival after surgery due to high incidence of metastasis in patients with 
breast, colon, prostate, and cervical cancer (22-27). In breast cancer high expression levels of 
CCL2 were a significant indicator of an early relapse (22). As a consequence, increased 
infiltration of tumor-associated macrophages resulted in higher vessel density due to 
angiogenesis (22, 28). In addition, CCL5 was found to be a predictive factor for stage II breast 
cancer patients and the co-expression of CCL2 and CCL5 in the same tumor was associated 
with a more advanced stage of the disease (23, 29). Microarray analysis of 2,254 human 
breast samples identified CCL5-CCR5 signaling to be preferentially active in the basal and 
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HER-2+ breast cancer subtypes (24). Importantly, CCR5 expression correlated with enhanced 
invasiveness and increased metastasis, and consequently, poor patient survival. Similarly, 
high CCL2 expression levels in colorectal cancer were linked to multiple enhanced liver 
metastases, and thereby, to poor prognosis for patients (25). In prostate cancer, CCL2 was 
produced in high amounts when compared to healthy epithelium (26). Interestingly, 
immunohistochemical staining of CCL2 revealed that not only tumor cells, but also 
surrounding stromal cells produced high levels of CCL2, suggesting autocrine and paracrine 
stimulation within the tumor microenvironment. CCL2 expression levels in prostate cancer 
correlated with the degree of tumor aggressiveness determined by Gleason score (26). In 
cervical cancer, the absence of CCL2 expression was associated with relapse-free survival 
(27). In all analyzed cancer types, CCL2 expression was associated with increased infiltration 
of tumor associated macrophages, which are known to be important for tumor progression, 
growth and angiogenesis.  
Some pancreatic and prostate cancers are spreading by perineural invasion that is defined as 
the presence of cancer cells in the perineural space (30). Prostate cancer cells express high 
levels of CX3CR1 compared to normal prostate epithelial cells which specifically binds to the 
transmembrane chemokine CX3CL1 expressed on neurons, nerve fibers and activated 
endothelium (31). In prostate cancer, enhanced CX3CR1 expression correlated with bone 
metastasis while in breast cancer CX3CR1 expression predicted occurrence of brain 
metastasis (32, 33).  
CXCL8 (IL-8) is a pro-inflammatory chemokine that is associated mainly with melanoma 
(34). CXCL8 expression levels in melanoma tumors and serum CXCL8 levels have been 
shown to correlate with tumor progression in melanoma patients (34, 35).  
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Acute Lymphoblastic Leukemia (ALL), a frequent childhood malignancy, is caused by 
genetic abnormalities. However, the mechanism providing a selective advantage for leukemia 
cells in the BM remains elusive. Recent findings indicate that bone-marrow plasma levels of 
CCL2 and CXCL8 are significantly elevated in patients at diagnosis compared to controls 
(36). Increased levels of CCL2 and CXCL8 in the bone marrow microenvironment enhanced 
adhesion of leukemia cells to the BM mesenchymal stem cells, and promoted their survival. 
CCL2 levels were also significantly increased in ALL patients with involvement in the CNS, 
and were further elevated during chemotherapy (37). However, further clinical evaluations are 
needed to assess the role of inflammatory chemokines during cancer progression. 
 
The chemokine-chemokine receptor axis forms the tumor microenvironment  
The tumor microenvironment at primary or metastatic sites can be actively shaped by tumor -
derived chemokines, resulting in the recruitment of leukocytes and activation of pro-
inflammatory mediators (1, 23, 38). It is currently accepted that inflammatory chemokines 
contribute to cancer progression by several mechanisms including: recruitment of 
inflammatory cells, immune suppression, angiogenesis and metastasis (Figure 1). While 
activation of chemokine receptors on stromal cells including leukocytes indirectly support 
cancer progression, engagement of chemokine receptors on tumor cells can directly influence 
their behavior and invasive capabilities. 
 
Chemokine receptors on tumor cells – influence the metastatic behavior 
Tumor-derived chemokines have been shown to directly affect tumor cells in an autocrine 
manner. Murine breast cancer cells expressing high levels of CCL5 spontaneously 
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metastasized to lungs and liver (39). Knock-down of CCL5 in 4T1 cells resulted in a strong 
reduction of metastasis and correlated with a reduced expression of MMP-2 and MMP-10. 
These findings suggested that CCL5 directly affected the metastatic capacity of 4T1 cells 
through modulation of MMP production. High-grade bladder cancer cells expressing high 
levels of CCL2 mediated their own increased migration and invasive capacity, when 
compared to low-grade bladder cancer cells expressing low CCL2 levels (40). Inhibition of 
CCR2 resulted in reduced invasiveness of bladder cancer cells and attenuated metastasis. 
Recent studies have shown that CCR2 overexpression in prostate cancer correlated with poor 
prognosis and that CCL2 signaling promoted tumor cell survival and metastasis to the bone 
(7, 41). This finding was further supported by the observation that CCL2 treatment of PC3 
prostate cancer cells protected them from nutrient-induced autophagic death through 
activation of the PI3K/Akt/survivin pathway (42). In breast cancer cells, up-regulated CCR2 
expression corresponded with increased CCL2 expression and resulted in improved survival 
(43). CCR2 knockdown in breast cancer cells significantly attenuated CCL2-driven cell 
migration and survival. Human malignant melanomas express and secrete high amounts of 
CXCL8 which correlated with enhanced metastasis (44). The majority of melanomas express 
CXCR2, the receptor for CXCL8; this has been shown to directly stimulate metastatic 
outgrowth (45). As expected, neutralization of CXCL8 attenuates experimental metastasis 
(46).  
 
Chemokines and angiogenesis  
Chemokines are critical mediators of neovascularization in many physiological and 
pathophysiological situations including cancer progression (47). Chemokines of the CXCL 
family can be divided into proangiogenic chemokines or angiostatic chemokines based on a 
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unique three amino acid sequence ELR. ELR-positive chemokines (e.g. CXCL1, CXCL2, 
CXCL8) promote angiogenesis by engaging the CXCR2 on endothelial cells (48). CXCR2 
has a critical role in neovascularization, since a CXCR2-neutralizing antibody blocked the 
proangiogenic activity of the CXCL8. In contrast, ELR-negative chemokines (e.g. CXCL4, 
CXCL9, CXCL10, CXCL11) have an angiostatic activity that is mediated through the 
CXCR3 on mononuclear cells (49). 
In addition to CXCL chemokines, CCL2 was reported to stimulate angiogenesis and 
chemotaxis of human microvascular endothelial cells in vitro, providing evidence for CCR2 
expression on endothelial cells (50, 51). Whether or not CCL2 directly stimulates 
angiogenesis remains controversial. It is believed to be dependent on the tissue origin of 
endothelial cells (50, 52). Direct stimulation of prostate cancer cells with CCL2 resulted in 
induced expression of pro-angiogenic factors like VEGF, suggesting an additional indirect 
effect on angiogenesis (53). Interestingly, the transcription factor Twist1 that induces 
epithelial to mesenchymal transition also promoted angiogenesis in mammary epithelial cells 
through CCL2-mediated recruitment of macrophages (54). Similarly, direct induction of 
VEGF expression and thereby angiogenesis has been proposed to be dependent on CCL2 
production and macrophage recruitment (22). Increased recruitment of F4/80+ macrophages to 
FGFR1-dependent breast cancer promoted angiogenesis in the mammary gland, which was 
dependent on CX3CL1 (55). These results support the notion that chemokine-recruited 
macrophages produce a number of cytokines that affect cancer progression including 
angiogenesis. 
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Immune suppression is modulated by CCL2  
Different tumors require various mechanisms to sustain their growth and to establish a 
suitable microenvironment for their persistence. Along this line, a mechanism of immune 
escape in melanoma has been documented to be CCL2-dependent (56, 57). Recruitment of 
monocytic CCR2+ myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment 
was shown to promote tumor growth through immune suppression (56). Ablation of CCR2+ 
MDSCs resulted in increased infiltration of activated cytotoxic CD8+ T-cells and reduced 
tumor growth. In non-small-cell lung cancer, the use of anti-CCL2 antibody significantly 
slowed down tumor growth and also inhibited spontaneous lung metastasis (57). Although no 
major difference in numbers of tumor-associated macrophages was detected, changes in their 
polarization status resulted in activation of CD8+ T-cells (57).  
 
CCL2-CCR2 anti-metastatic activity 
In contrast to the well-documented function of the CCL2-CCR2 axis in promoting metastasis, 
there are reports describing the opposite effect resulting in inhibition of tumor progression and 
metastasis (58, 59). Host-derived CCL2 and CCL3 recruited CD4+ and CD8+ lymphocytes 
and NK cells that controlled tumor progression and metastasis (60). Lung metastasis was 
enhanced by the deficiency of CCL2 and CCL3. Overexpression of CCL2 in 4T1 breast 
cancer cells resulted in reduced metastasis. However, the mechanism remained to be 
described (58). In an orthotopic breast cancer model using 4T1 cells, CCL2 had a pro-
tumorigenic activity at primary sites, while it inhibited metastasis to the lungs (59). Since 
down-regulation of CCL2 in tumor cells resulted in reduced primary tumor growth but 
accelerated metastasis, CCL2 was suggested to be essential for the entrainment of tumor-
associated neutrophils. Indeed, neutrophil depletion had no effect on the growth of primary 
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tumors, but resulted in enhanced lung metastasis indicating that neutrophils have a protective 
anti-metastatic trait. The switch between these anti- and pro-tumorigenic phenotypes was 
regulated by tumor cell-derived TGFβ (59, 61). However, there is conflicting data on the role 
of granulocytes/neutrophils during metastatic initiation. Kowanetz and colleagues showed that 
Ly6G+Ly6C+ cells (granulocytes) are recruited to the pre-metastatic lung by tumor-secreted 
G-CSF in 66c14 (a 4T1 sibling cell line) tumor-bearing mice (62). Depletion of granulocytes 
with anti-Gr1 or anti-Ly6G antibody reduced the number of lung metastases indicating that 
Ly6G+Ly6C+ cells contribute to the generation of lung metastases. Taken together, the role of 
CCL2 and respective CCR2+ cells during tumorigenesis and metastasis appears to be strongly 
dependent on the cellular composition, the tumor type and the stage of disease. In addition, 
the use of different mouse models and tumor cells are reflected in seemingly opposite 
observations. Being aware of these limitations, further experiments are required for dissection 
of the potentially ambivalent role of CCL2 during metastasis. 
 
Chemokines regulate leukocyte recruitment to metastatic sites 
Formation of a chemokine gradient on proteoglycans presented either in the extracellular 
matrix or on the endothelium is a prerequisite for leukocyte recruitment. Suppression of 
expression of the proteoglycan versican, led to reduced CCL2 binding and attenuation of 
metastasis (63). Versican promoted metastasis through enhancement of tumor-promoting 
inflammatory responses in the lungs and revealed CCL2 as a key factor in this process.  
Studies in various animal models confirmed that high expression levels of CCL2 and CCL5 
correlated with metastasis (64-68). Accordingly, the recruitment of CCR1-, CCR2-, and 
CCR5-positive monocytes and myeloid cells was associated with cancer progression. CCL5 
expression in breast cancer cells was linked to infiltration of CCR1- and CCR5-positive 
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leukocytes and promoted tumor growth (65, 69). The use of the CCR1 and CCR5 antagonist 
Met-CCL5 significantly reduced tumor growth of already established tumors (65). Further 
studies indicated concomitant expression of CCL2 and CCL5 in breast cancer cells that was 
associated with cancer progression and metastasis (23).  
In another model, overexpression of CCL2 in MDA-MB-231 human breast cancer cells 
promoted experimental metastasis to the lungs and the bone, while the use of neutralizing 
anti-CCL2 antibodies significantly reduced metastasis to these organs (64). Moreover, 
monocytic stromal cells expressing CCR2 contributed to breast cancer metastasis that was 
dependent on CCL2 produced from both tumors and stroma. The recruitment of circulating 
monocytic cells to metastatic sites has been identified as a critical factor for breast, colon, and 
lung cancer dissemination (66, 67). CCR2+ inflammatory monocytes were shown to promote 
tumor extravasation (66). Recently, we confirmed the critical role of CCR2-expressing 
inflammatory monocytes (CD11b+, Ly6Chi) that are recruited to metastasizing tumor cells 
(MC-38GFP colon or Lewis lung carcinoma 3LL) and facilitate efficient tumor cell 
extravasation (67). Intravenous injection of these cells in mice with specific depletion of 
CCR2 in the myeloid cell population (LysMCreCcr2loxP/loxP) resulted in reduced metastasis, 
directly confirming the essential role of CCR2+ monocytes during metastasis. In another 
study, a distinct population of CCR2+/CD11b/Gr1mid cells that promote experimental liver 
metastasis were identified, based on a significant reduction of metastasis after depletion of 
CD11b/Gr1mid cells (68). Interestingly, experimental metastasis of MC-38GFP and 3LL was 
found to be dependent on CCL2 expression by tumor cells (67, 68). Specific down-regulation 
of CCL2 in both MC-38 and 3LL cells resulted in a significantly reduced metastatic capacity, 
suggesting that direct interaction of the tumor cell-derived chemokine with monocytes is 
necessary for efficient tumor cell extravasation (67). In contrast, metastasis of B16-BL6 
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melanoma cells was independent of CCR2 expression, suggesting that some tumor cells use 
other means for tumor cell extravasation which remain to be determined (67, 68).  
These observations compellingly showed that CCL2 and CCL5-dependent recruitment of 
myeloid cells contribute to tumor cell colonization of distant organs including lungs, bones, 
and liver. However, the exact function of these cells during metastasis requires further 
analysis in the context of the metastatic microenvironment; the formation of which may 
already begin during the hematogenous phase.  
 
Tumor cell extravasation is dependent on endothelial CCR2 expression 
Recently, a novel role for the chemokine receptor CCR2 in facilitating tumor cell 
extravasation has been described (67). Significantly less lung metastasis developed in Ccr2-/- 
mice compared to wild-type mice using an experimental metastasis model. The lack of 
stromal CCR2 expression led to a reduced lung tumor burden compared to control mice. This 
suggested an important role for endothelial CCR2 expression in metastasis (Figure 2). Mice 
expressing CCR2 exclusively on endothelial cells under the Tie2 promoter consequently 
showed only a mild attenuation of metastasis compared to wild-type controls but had 
significantly more metastatic foci compared to Ccr2-/- mice. Furthermore, increase of vascular 
permeability and subsequent tumor cell extravasation was shown to be dependent on 
endothelial CCR2 expression. These observations were further confirmed in assays with 
primary lung endothelial cells isolated from wild-type and Ccr2-/- mice in vitro. Tumor cell 
transmigration through CCR2-deficient endothelial cells was significantly reduced, indicating 
the indispensable role for endothelial CCR2 in facilitating tumor cell transmigration and 
metastasis. 
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Inhibition of JAK2, the direct downstream mediator of CCR2, abolished the induction of lung 
permeability, inhibited tumor cell transmigration in the in vitro setting and attenuated 
metastasis (67). Downstream signaling of JAK2 was mediated through Stat5 and p38MAPK, 
the inhibition of which reduced lung vascular permeability and tumor cell extravasation. This 
was in agreement with previous findings that p38MAPK pathway is activated in endothelial 
cells by transmigrating tumor cells (70). However, the activation of the p38MAPK pathway as 
a consequence of a chemokine-chemokine receptor interaction has not been previously 
reported. Several studies are pointing towards an increased aggressiveness of various tumor 
types, including colon carcinoma and prostate cancer, when Stat5 signaling is constitutively 
activated in the tumor (71, 72). However, the role of Stat5 activation in promoting metastasis 
has not been previously assessed.  
In conclusion, the finding that endothelial CCR2 determines the efficacy of tumor cell 
extravasation indicates that CCR2-dependent recruitment of monocytic cells follows the 
initial increase in vascular permeability and enables efficient metastasis. It is likely that 
expression of CCR2 on endothelial cells during metastasis makes the inhibition of CCR2 a 
better target than inhibition of CCL2, which is present not only within the tumor but also in 
the circulation in significantly larger amounts. However, the dynamics of endothelial CCR2 
expression not only in the lungs but also other tissues remains to be determined. 
 
Stromal-derived chemokines regulate metastasis 
The cross-talk between tumor cells and the surrounding stroma is at least in part, mediated by 
chemokines that directly affect tumor progression. CCL2 produced by cancer-associated 
fibroblasts has been shown to regulate stromal-epithelial interactions in a breast cancer model 
(73). Targeted ablation of TGFβ signaling in fibroblasts resulted in enhanced CCL2 secretion 
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and increased recruitment of tumor-associated macrophages. The resulting increase in 
tumorigenesis and metastasis was abrogated with CCL2-neutralizing antibodies (73). 
Similarly, fibroblast-specific knock-down of CCL2 led to attenuated outgrowth of human 
breast cancer cells (74).  
During the hematogenous phase of metastasis, tumor cells also induce expression of 
chemokines by locally activated endothelium (75). Tumor cell-induced platelet-aggregation in 
the circulation promotes the arrest of metastasizing tumor cells in the vasculature and results 
in local endothelial activation and induced CCL5 expression in vivo. This process is 
facilitated by selectin-mediated interactions of tumor cells with platelets and leukocytes and 
further led to CCL5-dependent recruitment of circulating monocytes. Temporal inhibition of 
the CCL5 axis attenuated metastasis of both mouse and human colon carcinoma cells in an 
experimental metastasis mouse model (75). 
Another cell population contributing to breast cancer metastasis is mesenchymal stem cells 
(MSCs) (76). MSC-derived CCL5 production directly affected tumor cells which led to a 
significant increase in the metastatic behavior of otherwise poorly metastatic cells. Further 
analysis identified CCL5 as a factor enabling efficient extravasation of tumor cells.  
 
Chemokines and the metastatic niche 
There is accumulating evidence that tumor-derived factors enable mobilization of BM-derived 
cells, which in the context of certain tissues contribute to the formation of a pre-metastatic 
niche (77). BM-derived hematopoietic progenitor cells were shown to be recruited to the pre-
metastatic niche and to form cellular clusters before the arrival of tumor cells (78). The 
analysis of factors responsible for this process revealed inflammatory chemoattractants of the 
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S100 family as the major driver for the generation of the pre-metastatic niche (reviewed in 
79). The local production of S100A8 and S100A9 at pre-metastatic sites (e.g. endothelial and 
myeloid cells) is induced by factors released from primary tumors (80). One of the factors 
derived from the primary tumors is CCL5 which induced the release of S100A4 by stromal 
and tumor cells resulting in up-regulation of cytokines and chemokines (including G-CSF, 
CXCL5, CXCL3, CCL20, CCL5, CCL9) in tumor cells (81). CCL5-expressing tumor cells 
showed a significant reduction in lung metastasis in S100A4-/- mice, while liver metastasis 
was not affected, indicating that at least metastases to the lungs are highly dependent on the 
interplay between CCL5 and S100A4.  
Findings of tumor-derived factors responsible for the formation of a pre-metastatic niche 
raised the question of how specific tissues are targeted. Tumor-derived microvesicles, so-
called exosomes, were identified as transporters of stimulating factors to future metastatic 
sites (82). Melanoma-derived exosomes have been shown to induce lung vascular 
permeability and inflammation, thus generating a pre-metastatic niche in the tumor-targeted 
organ (83). Tumor-derived exosomes recruited MDSCs to the lungs of tumor bearing mice in 
a MyD88-dependent manner and thereby increased the metastatic burden (84). In addition, 
platelet-derived microvesicles have been shown to increase the metastatic potential of tumor 
cells (85). These data further support the notion that alteration in the tissue microenvironment 
may lead to pre-metastatic niche formation and promote metastasis to activated tissues. 
Whether and how inflammatory chemokines contribute to the formation of the pre-metastatic 
niche remains to be defined. 
The role of CCL2 in the development of bone metastasis involved CCR2+ stromal cells which 
promote the development and maintenance of bone metastases of prostate and breast cancer 
origin. Chemotaxis of prostate cancer cells is driven by CCL2, suggesting the possible 
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involvement of CCL2 in tissue specific migration to the bone (26, 86). In addition, an 
involvement of receptor activator of NF-κB ligand (RANKL) and CCL2 was reported in 
osteoclastogenesis and subsequent bone resorption that enabled metastasis of prostate cancer 
to the bone (41, 87). Similarly, CCL2 enhanced migration of breast cancer cells and has been 
suggested to mediate homing of breast cancer cells to the bone (88). However, these studies 
rely on the examination of prostate cancer cell lines and conditioned medium in vitro. 
Furthermore, prostate cancer-stimulated osteoblastic CCL2 production in the bone 
microenvironment was shown to be required for metastatic outgrowth (53). Mice carrying 
subcutaneous tumors of different prostate cancer cells induced CCL2 expression in the BM 
microenvironment which was mediated by tumor-derived parathyroid hormone-related 
protein secretion (53). The role of CCL2 on osteoclastogenesis was demonstrated in mice 
which were injected with prostate cancer cells in the tibia (53). Tumor growth in the bone was 
significantly attenuated by anti-CCL2 antibody treatment. Cyclophosphamide treatment of 
prostate cancer-bearing mice induced specific upregulation of cytokines and chemokines, 
including CCL2, in the BM that resulted in preferential recruitment of myeloid cells to these 
sites (89). The subsequent increase in bone metastasis could be reduced by anti-CCL2 
neutralizing antibody treatment. This study provided evidence that BM perturbation due to 
cytotoxic therapy may contribute to bone metastasis through a transient disruption of the BM 
vascular integrity and expansion of monocytes and neutrophils in the circulation. 
CX3CR1 expression on pancreatic and prostate cancer increased their invasiveness and 
specific metastasis to the neuronal tissues (30). The unique transmembrane expression of 
CX3CL1 on the cell surface of neurons and activated endothelium enabled also tumor cell 
adhesion (31). Overexpression of CX3CR1 in human pancreatic cells correlated with 
enhanced neuronal invasiveness in mice. The correlation between enhanced CX3CR1 
expression and bone metastases was shown also in breast cancer (90). The bone metastatic 
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cell line MDA-MB-231 expressed significant levels of CX3CR1 while MDA-MB-436, which 
does not metastasize to the bone, had undetectable levels. Experimental bone metastases of 
MDA-MB-231 cells were significantly reduced in CX3CL1-deficient mice (90). Functional 
CX3CR1 expression mediated adhesion of tumor cells to the endothelium since adhesion-
deficient mutant of CX3CR1 abrogate tumor cell recruitment to the bone.  
In summary, the contribution of chemokines to metastasis largely depends on the tissue at 
metastatic sites and cross-talk within the local microenvironment. Inflammatory chemokines 
promote tissue-specific metastasis and the current experimental evidence clearly links 
inflammatory chemokines to the formation of the metastatic niche which promotes tumor 
outgrowth in the lungs, liver and bone.  
 
Current concepts and future directions  
Efficient prevention of metastatic tumor spread or eradication of already existing metastasis 
has developed into one of the most important scientific, clinical and medical assignments in 
the last decade of cancer research (1). Efficient inhibition of metastasis by the targeting of 
tumor cells or specific host cells remains to be achieved. This is primarily due to the complex 
interplay between various host cell types and tumor cells. The concept of pharmacological 
inactivation of chemokines or chemokine receptors in order to reduce chemokine-dependent 
metastasis is under investigation and is not entirely new (7, 91). However, there are various 
obstacles that make inactivation of chemokines and their receptors in vivo a challenge:  
(1) The interactome of chemokines and chemokine receptors is highly complex, with 
various chemokines binding to one and the same receptor but also various chemokine 
receptors recognizing the same ligand.  
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(2) Inhibition of chemokine signaling may lead to compensatory effects resulting in 
changes of chemokine profiles (68).  
(3) Inactivation or inhibition of chemokine receptor-expressing cells may have severe 
consequences, due to the wide range of cells expressing chemokine receptors, 
although a time-defined treatment may be tolerated. 
(4) Since metastasis is a cascade of sequential and interlinked events, inactivation of 
specific chemokine-chemokine receptor functions may only be successful within a 
restricted time window. 
Thus, there is urgent need for novel tools (e.g. small molecules, function-blocking antibodies) 
and additional knowledge to successfully achieve a targeted and efficient inactivation of 
either chemokines or their receptors. Depending on the cancer stage, the number of circulating 
tumor cells and the degree of metastasis, a therapy aiming at preventing tumor cell 
extravasation may strongly reduce the risk of further cancer dissemination, but may not affect 
already established deposits. Thus, therapeutic approaches to inhibit chemokine receptor 
signaling for prevention of metastasis and to limit outgrowth of already established ones 
should be considered in future. Therefore, the goal will most likely be a combination therapy 
with targeting also tumor growth.  
Despite these open questions, inhibition of CCL2 or CCR2 was reported to be beneficial in 
inhibiting metastasis of various cancer types such as breast, bladder, colorectal or prostate 
cancer in experimental models (66-68). Based on this preclinical evidence, two clinical trials 
have been started, evaluating safety and efficacy of blocking both CCL2 and CCR2 in 
metastatic patients (http://www.clinicaltrials.gov: NCT00992186, NCT01015560). The 
initial trial for the treatment of patients with metastatic castration-resistant prostate cancer 
used the antibody “CNTO 888” which blocks CCL2. However, blocking CCL2 proved to be 
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less effective possibly due to induced compensatory mechanisms that led to an increase in 
CCL2 expression (68). In a second ongoing phase II trial, the anti-CCR2 antibody 
“MLN1202” is being used for treatment of patients with bone metastasis. Importantly, 
currently there is no anti-metastatic therapy clinically available, therefore additional criteria 
assessing efficacy will be required. Moreover, future studies will show whether additional 
chemokine-chemokine receptor pairs can be targeted for clinical evaluation.  
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Figure legends 
Figure 1: Direct effects of chemokines on the tumor microenvironment during cancer 
progression 
Chemokines secreted by tumor and stromal cells at primary tumor sites generate a chemokine 
gradient, which is required for the recruitment of leukocytes. Leukocyte recruitment, 
predominantly of myeloid-derived cells, supports tumor survival and helps to establish an 
immune-suppressive microenvironment. This tumor-protective environment hinders 
recruitment of tumor-attacking cells and causes their functional non-responsiveness. In 
addition, chemokines also have autocrine functions and may lead to acquisition of an invasive 
phenotype of tumor cells, a pre-requisite for the spread of tumors to distant organs. Prior to 
tumor cell arrest, formation of a pre-metastatic niche by BM-derived progenitor cells 
promotes metastatic seeding to certain organs. As tumor cells reach the targeted organ via the 
vascular system, they arrest on endothelial cells and trigger an inflammatory reaction. 
Induction of tumor cell extravasation is dependent on CCR2-mediated endothelial activation. 
This is followed by production of chemokines by tumor, endothelial and stromal cells and a 
recruitment of monocytic CCR2+ cells, enabling efficient tumor cell extravasation. At new 
sites, the cycle of chemokine gradient generation and recruitment of leukocytes leads to the 
generation of a metastatic microenvironment. This further promotes tumor cell proliferation 
and leads to the generation of metastatic lesions.  
Figure 2: CCL2-CCR2 mediated mechanisms in tumor cell extravasation 
A) Tumor cell-derived CCL2 leads to the recruitment of CCR2+ monocytes. Upon binding to 
endothelial CCR2, endothelial cells become activated and various signaling pathways are 
triggered. B) Triggering of endothelial CCR2 by CCL2 leads to phosphorylation of JAK2 
which subsequently can activate various downstream signaling pathways. Signaling through 
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Stat5 and p38MAPK pathways is important for tumor cell extravasation whereas Stat3, PI3K 
and Rac1 activation seems not to be involved. C) Activation of endothelial cells via the 
CCL2-CCR2-axis leads to cytoskeletal retraction within endothelial cells resulting in 
induction of vascular permeability. Disruption of the endothelial layer and gap formation 
between endothelial cells then allows transmigration of tumor cells together with monocytes. 
However, the exact dynamics and kinetics of cell-cell interactions promoting transmigration 
remain to be determined.  
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